TLW Venture Company

TLW Venture is a South Korean biotechnology company focused on the development of novel therapeutics for chronic liver diseases, particularly non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company's lead candidate, TLW-001, is a small molecule inhibitor of the Transforming Growth Factor-beta (TGF-β) signaling pathway, specifically targeting the ALK5 receptor to prevent and reverse fibrotic progression. TLW Venture is currently advancing TLW-001 through early-stage clinical trials to evaluate its safety, tolerability, and efficacy in patients with metabolic-associated steatohepatitis. Headquartered in South Korea, the firm leverages its specialized research in fibrotic mechanisms to address significant unmet needs in the hepatology space.